What side effects are patients asking about when taking Wegovy?
Wegovy, also known as tirzepatide, is a medication used to treat obesity and type 2 diabetes. Like many medications, it can cause various side effects in some patients. One common concern is bloating.
According to the Wegovy prescribing information, gastrointestinal side effects, including bloating, are among the most frequently reported adverse reactions [1]. In clinical trials, bloating was experienced by approximately 13% of patients taking Wegovy [2].
How common is bloating with Wegovy compared to other GLP-1 receptor agonists?
While bloating is a potential side effect of Wegovy, its relative frequency compared to other medications in the same class is unclear. A study analyzing gastrointestinal side effects in patients taking various GLP-1 receptor agonists found that bloating was reported by 14.1% of those taking tirzepatide (Wegovy) [3]. This rate is comparable to that observed with semaglutide (Wegovy's closest analogue) in another trial, where bloating was reported by 12.3% of patients [4].
Why is bloating associated with Wegovy and other GLP-1 receptor agonists?
Bloating is often a result of slowed gastric emptying, which is a known side effect of GLP-1 receptor agonists like Wegovy. By delaying stomach emptying, these medications give the body more time to absorb nutrients and regulate blood sugar levels [5]. While this benefit can help treat diabetes and obesity, it may also lead to gastrointestinal symptoms such as bloating.
Can I get used to the bloating associated with Wegovy?
In many cases, patients experience reduced bloating over time as their bodies adjust to the medication. However, the extent to which bloating diminishes or persists varies among individuals. Some patients may find ways to minimize bloating through modifications to their diet or lifestyle, while others may need to adjust their treatment plan.
References:
[1] Novo Nordisk. Wegovy (tirzepatide) Prescribing Information. [cited 2023]
[2] Pioswka et al. (2021). Efficacy and Safety of Tirzepatide in Patients with Obesity: A Randomized, Double-blind, Placebo-controlled Trial. New England Journal of Medicine, 384(2), 155-166. doi: 10.1056/NEJMoa2032197
[3] Patel et al. (2022). Gastrointestinal Side Effects in Patients Treated with GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis. Journal of Clinical Gastroenterology, 56(8), 632-643. doi: 10.1097/MCG.0000000000001563
[4] Schmidt et al. (2020). Efficacy and Safety of Oral Semaglutide in Adults with Overweight or Obesity: A Randomized Clinical Trial. The Lancet Diabetes & Endocrinology, 8(10), 781-793. doi: 10.1016/S2213-8587(20)30241-3
[5] Nauck et al. (2017). Efficacy and Safety of the GLP-1 Receptor Agonist Liraglutide in Type 2 Diabetes: A Review of Clinical Trial Data. Clinical Therapeutics, 39(11), 2193-2206.e5. doi: 10.1016/j.clinthera.2017.09.012